Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Geriatrics
Published in: BMC Geriatrics 1/2024

Open Access 01-12-2024 | Obesity | Systematic Review

Prevalence of sarcopenic obesity in the older non-hospitalized population: a systematic review and meta-analysis

Authors: Yuhong Luo, Yanqiu Wang, Shuao Tang, Ludan Xu, Xinyu Zhao, Mengya Han, Yuhua Liu, Yan Xu, Binru Han

Published in: BMC Geriatrics | Issue 1/2024

Login to get access

Abstract

Background

Sarcopenic obesity emerges as a risk factor for adverse clinical outcomes in non-hospitalized older adults, including physical disabilities, metabolic diseases, and even mortality. In this systematic review and meta-analysis, we investigated the overall SO prevalence in non-hospitalized adults aged ≥ 65 years and assessed the sociodemographic, clinicobiological, and lifestyle factors related to SO.

Methods

We searched the PubMed, Embase, Cochrane Library, and Web of Science databases for studies reporting the prevalence of SO from database inception to October 2023. Two researchers independently screened the literature, evaluated the study quality, and extracted the data. Both fixed- and random-effects models were used in the meta-analysis to estimate the pooled SO prevalence and perform subgroup analyses. Publication and sensitivity bias analyses were performed to test the robustness of the associations.

Results

Among 46 studies eligible for review and a total of 71,757 non-hospitalized older adults, the combined prevalence of SO was 14% (95% CI:11–17%, I2 = 99.5%, P < 0.01). Subgroup analysis according to lifestyle factors demonstrated that the SO prevalence was 17% (95% CI: 8–29%, I2 = 99.5%, P < 0.01) in older adults without exercise habits. Regarding clinicobiological factors, older adults with a history of falls (15% [95% CI: 10–22%, I2 = 82%, P < 0.01]), two or more chronic diseases (19% [95% CI: 10–29%, I2 = 97%, P < 0.01]), functional impairment (33% [95% CI: 29–37%, I2 = 0%, P = 0.95]), cognitive impairment (35% [95% CI: 9–65%, I2 = 83%, P = 0.02]), osteoporosis (20% [95% CI: 8–35%, I2 = 96%, P < 0.01]), high fasting glucose level (17% [95% CI: 1–49%, I2 = 98%, P < 0.01]), or the use of antipsychotics (13% [95% CI: 2–28%, I2 = 0%, P = 0.32]) exhibited a higher SO prevalence.

Conclusion

SO prevalence is high among non-hospitalized older adults, especially those with functional and cognitive impairments. Thus, SO is a potential problem for the aging population; implementation of planned interventions in the community is needed to reduce the prevalence and adverse outcomes of SO.
Appendix
Available only for authorised users
Literature
1.
Park MJ, Choi KM. Interplay of skeletal muscle and adipose tissue: sarcopenic obesity. Metabolism. 2023;144:155577.PubMedCrossRef
2.
Lim S, Kim JH, Yoon JW, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care. 2010;33(7):1652–4.PubMedPubMedCentralCrossRef
3.
Kim TN, Yang SJ, Yoo HJ, et al. Prevalence of Sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study. Int J Obes (Lond). 2009;33(8):885–92.PubMedCrossRef
4.
Baek SJ, Nam GE, Han KD, et al. Sarcopenia and sarcopenic obesity and their association with dyslipidemia in Korean elderly men: the 2008–2010 Korea National Health and Nutrition Examination Survey. J Endocrinol Invest. 2014;37(3):247–60.PubMedCrossRef
5.
Gao Q, Mei F, Shang Y, et al. Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis. Clin Nutr. 2021;40(7):4633–41.PubMedCrossRef
6.
Daskalopoulou C, Wu YT, Pan W, et al. Factors related with Sarcopenia and sarcopenic obesity among low- and middle-income settings: the 10/66 DRG study. Sci Rep. 2020;10(1):20453.PubMedPubMedCentralCrossRef
7.
de Campos GC, Lourenço RA, Lopes CS. Prevalence of Sarcopenic Obesity and its Association with functionality, lifestyle, biomarkers and morbidities in older adults: the FIBRA-RJ Study of Frailty in older Brazilian adults. Clin (Sao Paulo). 2020;75:e1814.CrossRef
8.
Lim HS, Park YH, Suh K, et al. Association between Sarcopenia, Sarcopenic Obesity, and Chronic Disease in Korean Elderly. J Bone Metab. 2018;25(3):187–93.PubMedPubMedCentralCrossRef
9.
Dondero KR, Falvey JR, Beamer BA, et al. Geriatric vulnerabilities among obese older adults with and without Sarcopenia: findings from a nationally Representative Cohort Study. J Geriatr Phys Ther. 2022;46(3):168–73.PubMedPubMedCentralCrossRef
10.
Hwang J, Park S. Gender-specific prevalence and risk factors of sarcopenic obesity in the Korean Elderly Population: a nationwide cross-sectional study. Int J Environ Res Public Health. 2023;20(2):1140.PubMedPubMedCentralCrossRef
11.
Batsis JA, Barre LK, Mackenzie TA, et al. Variation in the prevalence of Sarcopenia and sarcopenic obesity in older adults associated with different research definitions: dual-energy X-ray absorptiometry data from the National Health and Nutrition Examination Survey 1999–2004. J Am Geriatr Soc. 2013;61(6):974–80.PubMedCrossRef
12.
Donini LM, Busetto L, Bauer JM, et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clin Nutr. 2020;39(8):2368–88.PubMedCrossRef
13.
Du Y, Wang X, Xie H, et al. Sex differences in the prevalence and adverse outcomes of Sarcopenia and sarcopenic obesity in community dwelling elderly in East China using the AWGS criteria. BMC Endocr Disord. 2019;25(1):109.CrossRef
14.
Campos GC, Lourenço RA, Molina MDCB. Mortality, sarcopenic obesity, and Sarcopenia: Frailty in Brazilian older people Study - FIBRA - RJ. Rev Saude Publica. 2021;55:75.PubMedPubMedCentralCrossRef
15.
Tyrovolas S, Koyanagi A, Olaya B, et al. Factors associated with skeletal muscle mass, Sarcopenia, and sarcopenic obesity in older adults: a multi-continent study. J Cachexia Sarcopenia Muscle. 2016;7(3):312–21.PubMedCrossRef
16.
Son J, Yu Q, Seo JS. Sarcopenic obesity can be negatively associated with active physical activity and adequate intake of some nutrients in Korean elderly: findings from the Korea National Health and Nutrition Examination Survey (2008–2011). Nutr Res Pract. 2019;13(1):47–57.PubMedPubMedCentralCrossRef
17.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.PubMedPubMedCentralCrossRef
18.
Munn Z, Moola S, Lisy K, et al. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147–53.PubMedCrossRef
19.
Batsis JA, Haudenschild C, Roth RM, et al. Incident impaired cognitive function in sarcopenic obesity: data from the National Health and Aging trends Survey. J Am Med Dir Assoc. 2021;22(4):865–e8725.PubMedCrossRef
20.
Scott D, Blyth F, Naganathan V, et al. Sarcopenia prevalence and functional outcomes in older men with obesity: comparing the use of the EWGSOP2 Sarcopenia versus ESPEN-EASO sarcopenic obesity consensus definitions. Clin Nutr. 2023;42(9):1610–8.PubMedCrossRef
21.
Kim JE, Choi J, Kim M, et al. Assessment of existing anthropometric indices for screening sarcopenic obesity in older adults. Br J Nutr. 2023;129(5):875–87.PubMedCrossRef
22.
Ulugerger Avci G, Bektan Kanat B, Can G, et al. The impact of Sarcopenia and obesity on mortality of older adults: five years results. Ir J Med Sci. 2023;192(5):2209–16.PubMedCrossRef
23.
Scott D, Cumming R, Naganathan V, et al. Associations of sarcopenic obesity with the metabolic syndrome and insulin resistance over five years in older men: the Concord Health and Ageing in Men Project. Exp Gerontol. 2018;108:99–105.PubMedCrossRef
24.
Kemmler W, Teschler M, Weißenfels A, et al. Prevalence of Sarcopenia and sarcopenic obesity in older German men using recognized definitions: high accordance but low overlap! Osteoporos Int. 2017;28(6):1881–91.PubMedCrossRef
25.
Morikawa M, Lee S, Makino K, et al. Sarcopenic obesity and risk of disability in Community-Dwelling Japanese older adults: a 5-Year longitudinal study. J Am Med Dir Assoc. 2023;24(8):1179–e11841.PubMedCrossRef
26.
Peng TC, Chen WL, Chen YY, et al. Associations between different measurements of sarcopenic obesity and health outcomes among non-frail community-dwelling older adults in Taiwan. Br J Nutr. 2021;126(11):1749–57.PubMedCrossRef
27.
Rossi AP, Urbani S, Fantin F, et al. Worsening disability and hospitalization risk in Sarcopenic obese and dynapenic abdominal obese: a 5.5 years Follow-Up study in Elderly men and women. Front Endocrinol (Lausanne). 2020;11:314.PubMedCrossRef
28.
Someya Y, Tamura Y, Kaga H, et al. Sarcopenic obesity is associated with cognitive impairment in community-dwelling older adults: the Bunkyo Health Study. Clin Nutr. 2022;41(5):1046–51.PubMedCrossRef
29.
von Berens Å, Obling SR, Nydahl M, et al. Sarcopenic obesity and associations with mortality in older women and men - a prospective observational study. BMC Geriatr. 2020;20(1):199.CrossRef
30.
Mendham AE, Goedecke JH, Micklesfield LK, et al. Understanding factors associated with sarcopenic obesity in older African women from a low-income setting: a cross-sectional analysis. BMC Geriatr. 2021;21(1):247.PubMedPubMedCentralCrossRef
31.
Moreno-Franco B, Pérez-Tasigchana RF, Lopez-Garcia E, et al. Socioeconomic determinants of sarcopenic obesity and frail obesity in community-dwelling older adults: the Seniors-ENRICA Study. Sci Rep. 2018;8(1):10760.PubMedPubMedCentralCrossRef
32.
Nascimento DDC, Oliveira SDC, Vieira DCL, et al. The impact of sarcopenic obesity on inflammation, lean body mass, and muscle strength in elderly women. Int J Gen Med. 2018;22:11:443–9.CrossRef
33.
Aibar-Almazán A, Martínez-Amat A, Cruz-Díaz D, et al. Sarcopenia and sarcopenic obesity in Spanish community-dwelling middle-aged and older women: Association with balance confidence, fear of falling and fall risk. Maturitas. 2018;107:26–32.PubMedCrossRef
34.
Diago-Galmés A, Guillamón-Escudero C, Tenías-Burillo JM, et al. Salivary testosterone and cortisol as biomarkers for the diagnosis of Sarcopenia and sarcopenic obesity in Community-Dwelling older adults. Biology (Basel). 2021;10(2):93.PubMed
35.
dos Santos EP, Gadelha AB, Safons MP, et al. Sarcopenia and sarcopenic obesity classifications and cardiometabolic risks in older women. Arch Gerontol Geriatr. 2014;59(1):56–61.PubMedCrossRef
36.
Dutra MT, Gadelha AB, Nóbrega OT, et al. Body Adiposity Index, but not visceral Adiposity Index, correlates with inflammatory markers in Sarcopenic obese Elderly women. Exp Aging Res. 2017;43(3):291–304.PubMedCrossRef
37.
Fonfría-Vivas R, Pérez-Ros P, Barrachina-Igual J, et al. Assessing quality of life with SarQol is useful in screening for Sarcopenia and sarcopenic obesity in older women. Aging Clin Exp Res. 2023;35(10):2069–79.PubMedPubMedCentralCrossRef
38.
Halil M, Ulger Z, Varlı M, et al. Sarcopenia assessment project in the nursing homes in Turkey. Eur J Clin Nutr. 2014;68(6):690–4.PubMedCrossRef
39.
Ida S, Kaneko R, Imataka K, et al. Incidence of sarcopenic obesity in older patients with diabetes and association between sarcopenic obesity and higher-level functional capacity: evaluation based on a consensus statement. Endocr J. 2023;70(6):591–9.PubMedCrossRef
40.
Ishii S, Chang C, Tanaka T, et al. The Association between SarcopenicObesity and depressive symptoms in older Japanese adults. PLoS ONE. 2016;11(9):e0162898.PubMedPubMedCentralCrossRef
41.
Kera T, Kawai H, Hirano H, et al. Differences in body composition and physical function related to pure Sarcopenia and sarcopenic obesity: a study of community-dwelling older adults in Japan. Geriatr Gerontol Int. 2017;17(12):2602–9.PubMedCrossRef
42.
Kim J, Baek Y, Jeong K, et al. Association of Dietary factors with grip Strength, Body Fat, and prevalence of sarcopenic obesity in rural Korean Elderly with Cardiometabolic Multimorbidity. Front Nutr. 2022;9:910481.PubMedPubMedCentralCrossRef
43.
Lee JH, Park HM, Lee YJ. Using Dietary Macronutrient patterns to predict sarcopenic obesity in older adults: a Representative Korean Nationwide Population-based study. Nutrients. 2021;13(11):4031.PubMedPubMedCentralCrossRef
44.
Lu L, He X, Song Y, et al. Prevalence and risk factors of Sarcopenia without obesity and sarcopenic obesity among Chinese community older people in suburban area of Shanghai: a cross-sectional study. Front Aging Neurosci. 2022;14:1034542.PubMedPubMedCentralCrossRef
45.
Park JE, Lee S, Kim K. The effect of combining nutrient intake and physical activity levels on central obesity, Sarcopenia, and sarcopenic obesity: a population-based cross-sectional study in South Korea. BMC Geriatr. 2023;23(1):119.PubMedPubMedCentralCrossRef
46.
Pedrero-Chamizo R, Gómez-Cabello A, Meléndez A, et al. Higher levels of physical fitness are associated with a reduced risk of suffering sarcopenic obesity and better perceived health among the elderly: the EXERNET multi-center study. J Nutr Health Aging. 2015;19(2):211–7.PubMedCrossRef
47.
Schluessel S, Huemer MT, Peters A, et al. Sarcopenic obesity using the ESPEN and EASO consensus statement criteria of 2022 - results from the German KORA-Age study. Obes Res Clin Pract. 2023;17(4):349–52.PubMedCrossRef
48.
Teixeira LAC, Avelar NCP, Parentoni AN, et al. Inflammatory biomarkers in older women with obesity, Sarcopenia, and sarcopenic obesity. J Am Med Dir Assoc. 2023;24(10):1562–4.PubMedCrossRef
49.
Yang CW, Li CI, Li TC, et al. Association of Sarcopenic Obesity with higher serum high-sensitivity C-Reactive protein levels in Chinese older Males–A Community-based study (Taichung Community Health Study-Elderly, TCHS-E). PLoS ONE. 2015;10(7):e0132908.PubMedPubMedCentralCrossRef
50.
Yang M, Hu M, Zhang Y, et al. Sarcopenic obesity is associated with frailty among community-dwelling older adults: findings from the WCHAT study. BMC Geriatr. 2022;22(1):863.PubMedPubMedCentralCrossRef
51.
Mo YH, Yang C, Su YD, et al. Prevalence and diagnostic agreement of sarcopenic obesity with different definitions among Chinese community-dwelling older adults. Age Ageing. 2022;51(1):afab272.PubMedCrossRef
52.
53.
Altinkaynak M, Ozturk CK, Goksoy Y, et al. The prevalence of sarcopenic obesity and its relationship with type 2 diabetes in a nursing home. Eur Rev Med Pharmacol Sci. 2023;27(7):2858–64.PubMed
54.
Jang W, Kim H. Association of socioeconomic factors and dietary intake with sarcopenic obesity in the Korean older population. Asia Pac J Clin Nutr. 2023;32(3):348–55.PubMed
55.
Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metab Clin Exp. 2019;92:6e10.CrossRef
56.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older people. Age Ageing. 2010;39(4):412–23.PubMedPubMedCentralCrossRef
57.
Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–e3072.PubMedCrossRef
58.
Studenski SA, Peters KW, Alley DE et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547– 58.
59.
Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on Sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56.PubMedCrossRef
60.
Xu W, Zhang H, Paillard-Borg S, et al. Prevalence of overweight and obesity among Chinese adults: role of Adiposity indicators and Age. Obes Facts. 2016;9(1):17–28.PubMedPubMedCentralCrossRef
61.
Molino S, Dossena M, Buonocore D, et al. Sarcopenic obesity: an Appraisal of the current status of knowledge and management in Elderly people. J Nutr Health Aging. 2016;20(7):780–8.PubMedCrossRef
62.
Bouchard DR, Choquette S, Dionne IJ, et al. Is fat mass distribution related to impaired mobility in older men and women? Nutrition as a determinant of successful aging: the Quebec longitudinal study. Exp Aging Res. 2011;37(3):346–57.PubMedCrossRef
63.
64.
Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513–37.PubMedPubMedCentralCrossRef
65.
Liu X, Hao Q, Yue J, et al. Sarcopenia, obesity and Sarcopenia obesity in comparison: Prevalence, Metabolic Profile, and key differences: results from WCHAT Study. J Nutr Health Aging. 2020;24(4):429–37.PubMedCrossRef
66.
Zamboni M, Mazzali G, Fantin F, et al. Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis. 2008;18(5):388–95.PubMedCrossRef
67.
Shimokata H, Ando F, Yuki A, et al. Age-related changes in skeletal muscle mass among community-dwelling Japanese: a 12-year longitudinal study. Geriatr Gerontol Int. 2014;14(Suppl 1):85–92.PubMedCrossRef
68.
Tiidus PM. Benefits of estrogen replacement for skeletal muscle mass and function in post-menopausal females: evidence from human and animal studies. Eurasian J Med. 2011;43(2):109–14.PubMedPubMedCentralCrossRef
69.
70.
Okazaki K, Yazawa D, Goto M, et al. Effects of macronutrient intake on thigh muscle mass during home-based walking training in middle-aged and older women. Scand J Med Sci Sports. 2013;23(5):e286–92.PubMedCrossRef
71.
Chomentowski P, Dubé JJ, Amati F, et al. Moderate exercise attenuates the loss of skeletal muscle mass that occurs with intentional caloric restriction-induced weight loss in older, overweight to obese adults. J Gerontol Biol Sci Med Sci. 2009;64(5):575–80.CrossRef
72.
Kitamura A, Seino S, Abe T, et al. Sarcopenia: prevalence, associated factors, and the risk of mortality and disability in Japanese older adults. J Cachexia Sarcopenia Muscle. 2021;12(1):30–8.PubMedCrossRef
73.
Jeong SM, Choi S, Kim K, et al. Association among handgrip strength, body mass index and decline in cognitive function among the elderly women. BMC Geriatr. 2018;18(1):225.PubMedPubMedCentralCrossRef
74.
Gustafson D, Lissner L, Bengtsson C, et al. A 24-year follow-up of body mass index and cerebral atrophy. Neurology. 2004;63(10):1876–81.PubMedCrossRef
75.
76.
77.
Noubiap JJ, Balti EV, Bigna JJ, et al. Dyslipidaemia in Africa-comment on a recent systematic review - authors’ reply. Lancet Glob Health. 2019;7(3):e308–9.PubMedCrossRef
Metadata
Title
Prevalence of sarcopenic obesity in the older non-hospitalized population: a systematic review and meta-analysis
Authors
Yuhong Luo
Yanqiu Wang
Shuao Tang
Ludan Xu
Xinyu Zhao
Mengya Han
Yuhua Liu
Yan Xu
Binru Han
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2024
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-024-04952-z

Other articles of this Issue 1/2024

BMC Geriatrics 1/2024 Go to the issue

Research

Causal associations between leisure sedentary behaviors and sleep status with frailty: insight from Mendelian randomization study

Research

Translation and validation of the audiovisual version of the Montreal cognitive assessment in older adults in Brazil

Research

Cannabis use in a Canadian long-term care facility: a case study

Research

Recognition of cognitive dysfunction in hospitalised older patients: a flash mob study

Research

Socioeconomic variation in the prevalence of pain by anatomical sites among middle-aged and older adults in India: a cross-sectional study

Research

Process evaluation of a tailored nudge intervention to promote appropriate care and treatment of older patients at the end-of-life
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits